Jefferies analyst Anthony Petrone raised his price target on Antares Pharma to $7 from $5, calling FDA approval of Xyosted a "game changer." He does not believe the inclusion of a black box warning in the label is a significant surprise nor a deal breaker for doctors, Petrone tells investors. The analyst, who thinks the company could take anywhere from 20% to 60% of the $1.5B-$2.0B TRT market over time, sees upside to $15 on a strong roll out of Xyosted, he added. Petrone keeps a Buy rating on Antares shares, which are up 17.5% to $3.83 in afternoon trading.